| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
8 companies
Heron Patrick J is a Director, 10% Owner at MBX Biosciences, Inc. with holdings across 8 companies. Recent SEC Form 4 filings include 17 buys and 0 sells.
Estimated insider holdings value: $324.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 26, 2025 | MBX Mbx Biosciences, Inc. | Director, 10% Owner | Buy | 666,666 | $18.00 | $11,999,988.00 | +14.6% | +76.5% | - | |
| Jun 13, 2025 | ARQT Arcutis Biotherapeutics, Inc. | - | Buy | 2,646 | $13.08 | $34,610.47 | +10.7% | +31.7% | - | |
| Jun 5, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Director | Buy | 2,268 | $13.34 | $30,246.73 | +4.8% | +18.0% | - | |
| May 22, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Director | Buy | 5,040 | $13.66 | $68,821.20 | +13.4% | +15.6% | - | |
| May 15, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Director | Buy | 2,520 | $13.62 | $34,316.86 | +16.8% | +14.7% | - | |
| May 14, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Director | Buy | 8,674 | $13.76 | $119,351.93 | +57.9% | +8.4% | - | |
| May 9, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Director | Buy | 6,300 | $13.60 | $85,691.34 | New | +4.4% | - | |
| Mar 17, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 549 | $44.11 | $24,214.01 | +0.2% | +11.7% | +113.8% | |
| Mar 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 2,298 | $43.31 | $99,517.93 | +0.5% | +6.8% | +108.2% | |
| Mar 7, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 1,915 | $43.69 | $83,661.30 | +0.6% | +2.7% | +98.4% |